

Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia

Carolin Heller ¹, Martha S Foiani ¹, Katrina Moore ², Rhian Convery ²,
Martina Bocchetta ², Mollie Neason ², David M Cash,^{2,3} David Thomas ⁴,
Caroline V Greaves ², Ione OC Woollacott ², Rachele Shafei ²,
John C Van Swieten ⁵, Fermin Moreno,⁶ Raquel Sanchez-Valle,⁷
Barbara Borroni ⁸, Robert Laforce Jr,⁹ Mario Masellis,¹⁰ Maria Carmela Tartaglia,¹¹
Caroline Graff,¹² Daniela Galimberti,^{13,14} James B Rowe ¹⁵, Elizabeth Finger ¹⁶,
Matthis Synofzik,^{17,18} Rik Vandenberghe,¹⁹ Alexandre de Mendonca,²⁰
Fabrizio Tagliavini,²¹ Isabel Santana,²² Simon Ducharme,²³ Christopher R Butler,²⁴
Alex Gerhard,²⁵ Johannes Levin,^{26,27,28} Adrian Danek,²⁷ Giovanni Frisoni,²⁹
Sandro Sorbi,³⁰ Markus Otto ³¹, Amanda J Heslegrave,¹ Henrik Zetterberg,^{1,32}
Jonathan D Rohrer ², on behalf of GENFI

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2019-321954>).

For numbered affiliations see end of article.

Correspondence to

Dr Jonathan D Rohrer, Dementia Research Centre, UCL Institute of Neurology, London, UK; j.rohrer@ucl.ac.uk

Received 28 August 2019
Revised 20 November 2019
Accepted 2 December 2019
Published Online First 14 January 2020



© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Heller C, Foiani MS, Moore K, et al. *J Neurol Neurosurg Psychiatry* 2020;**91**:263–270.

ABSTRACT

Background There are few validated fluid biomarkers in frontotemporal dementia (FTD). Glial fibrillary acidic protein (GFAP) is a measure of astrogliosis, a known pathological process of FTD, but has yet to be explored as potential biomarker.

Methods Plasma GFAP and neurofilament light chain (NfL) concentration were measured in 469 individuals enrolled in the Genetic FTD Initiative: 114 *C9orf72* expansion carriers (74 presymptomatic, 40 symptomatic), 119 *GRN* mutation carriers (88 presymptomatic, 31 symptomatic), 53 *MAPT* mutation carriers (34 presymptomatic, 19 symptomatic) and 183 non-carrier controls. Biomarker measures were compared between groups using linear regression models adjusted for age and sex with family membership included as random effect. Participants underwent standardised clinical assessments including the Mini-Mental State Examination (MMSE), Frontotemporal Lobar Degeneration–Clinical Dementia Rating scale and MRI. Spearman's correlation coefficient was used to investigate the relationship of plasma GFAP to clinical and imaging measures.

Results Plasma GFAP concentration was significantly increased in symptomatic *GRN* mutation carriers (adjusted mean difference from controls 192.3 pg/mL, 95% CI 126.5 to 445.6), but not in those with *C9orf72* expansions (9.0, –61.3 to 54.6), *MAPT* mutations (12.7, –33.3 to 90.4) or the presymptomatic groups. GFAP concentration was significantly positively correlated with age in both controls and the majority of the disease groups, as well as with NfL concentration. In the presymptomatic period, higher GFAP concentrations were correlated with a lower cognitive score (MMSE) and lower brain volume, while in the symptomatic period, higher concentrations were associated with faster rates of atrophy in the temporal lobe.

Conclusions Raised GFAP concentrations appear to be unique to *GRN*-related FTD, with levels potentially increasing just prior to symptom onset, suggesting that

GFAP may be an important marker of proximity to onset, and helpful for forthcoming therapeutic prevention trials.

INTRODUCTION

Frontotemporal dementia (FTD) is a progressive neurodegenerative condition with around a third of cases caused by an autosomal dominant gene mutation in progranulin (*GRN*), chromosome 9 open reading frame 72 (*C9orf72*) or microtubule-associated protein tau (*MAPT*).¹ As clinical trials in genetic FTD are fast approaching, robust biomarkers that allow accurate measurement of disease onset and progression are becoming increasingly important. In particular, many trials will focus on the presymptomatic stage of disease where neuropathological alterations are already present² and yet few biomarkers have been shown to be abnormal in this phase.^{3–5}

Cerebrospinal fluid (CSF) or plasma/serum progranulin levels in *GRN* mutation carriers^{4,6} and CSF (poly)GP dipeptide repeat concentrations in *C9orf72* expansion carriers^{5,7,8} are markers of specific protein abnormalities in genetic FTD, but both are abnormal from early in the presymptomatic period (and potentially from birth). In contrast, neurofilament light chain (NfL) is a marker of neuronal death and axonal degeneration (measurable in CSF^{3,9,10} as well as both plasma¹¹ and serum^{12,13}) that is not specific to FTD¹⁴ and has only been shown to be abnormal in the very late presymptomatic period prior to conversion to the symptomatic phase.³ Glial fibrillary acidic protein (GFAP) is a marker of astrogliosis, the abnormal proliferation of astrocytes due to neuronal damage¹⁵ and has previously been shown to be increased in frontal cortical tissue in FTD,¹⁶ and raised in both the CSF and serum of patients with symptomatic FTD.^{17–19} However, it has yet to be

Table 1 Demographic, cognitive and biomarker data from study participants

	Controls	Presymptomatic mutation carriers			Symptomatic mutation carriers		
		<i>C9orf72</i>	<i>GRN</i>	<i>MAPT</i>	<i>C9orf72</i>	<i>GRN</i>	<i>MAPT</i>
Number of participants	183	74	88	34	40	31	19
Sex: number male (%)	81 (44.3)	29 (39.2)	34 (38.6)	13 (38.2)	27*† (67.5)	16 (51.6)	11 (57.9)
Median (IQR) age (years)	43.8 (36.3–55.1)	44.1 (34.4–52.9)	42.4 (34.6–52.7)	36.2* (31.6–44.9)	66.0*† (60.7–71.4)	64.3*‡ (59.9–70.2)	58.3*§ (53.9–64.3)
Mean (range) age at onset (years)	N/A	N/A	N/A	N/A	59 (34–71)	61 (49–76)	53 (37–66)
Median (IQR) disease duration (years)	N/A	N/A	N/A	N/A	5.6 (3.6–6.9)	2.6 (1.6–4.3)	4.3 (2.5–9.3)
Diagnosis	N/A	N/A	N/A	N/A	30 bvFTD, 8 ALS/FTD-ALS, 1 PPA, 1 PSP	15 bvFTD, 14 PPA, 1 CBS, 1 other	19 bvFTD
Median (range) MMSE	30 (26–30)	30 (25–30)	30 (26–30)	30 (27–30)	26*† (7–30)	22*‡ (0–29)	24*§ (6–30)
Median (range) FTLD-CDR-SOB	0.0 (0.0–3.0)	0.0 (0.0–3.0)	0.0 (0.0–2.5)	0.0 (0.0–2.5)	10.0*† (0.0–22.0)	10.5*‡ (2.0–21.0)	8.5*§ (1.0–21.0)
Median (IQR) plasma NfL (pg/mL)	9.3 (6.8–13.0)	11.3 (8.3–17.0)	9.2 (7.0–12.8)	8.4 (6.3–9.7)	46.0 (22.8–62.6)	92.7 (54.8–130.1)	20.5 (15.4–37.6)
Median (IQR) plasma GFAP (pg/mL)	105.8 (80.4–146.1)	116.1 (88.3–180.0)	113.4 (80.5–168.1)	89.1 (70.9–151.0)	165.7 (124.8–245.3)	272.2 (211.5–417.8)	123.3 (85.2–206.7)

For sex, age, MMSE and FTLD-CDR-SOB, significant differences are shown at $p < 0.05$:

*Compared with controls.

†In *C9orf72* group between symptomatic and presymptomatic carriers.

‡In *GRN* group between symptomatic and presymptomatic carriers.

§In *MAPT* group between symptomatic and presymptomatic carriers.

ALS, amyotrophic lateral sclerosis; bvFTD, behavioural variant frontotemporal dementia; CBS, corticobasal syndrome; FTLD-CDR-SOB, Frontotemporal Lobar Degeneration-Clinical Dementia Rating scale-Sum Of Boxes; GFAP, glial fibrillary acidic protein; MMSE, Mini-Mental State Examination; N/A, not applicable; NfL, neurofilament light chain; PPA, primary progressive aphasia; PSP, progressive supranuclear palsy.

explored using ultrasensitive blood-based assays in genetic FTD mutation carriers.

In this study, we aimed to investigate within the Genetic FTD Initiative (GENFI) cohort whether plasma GFAP was abnormal in each of the different genetic FTD groups during the symptomatic period, and whether we could detect any presymptomatic changes. We also aimed to explore the relationship of GFAP with plasma NfL, cognitive, and neuroimaging measures.

METHODS

Participants

Participants were recruited from GENFI, a natural history study of genetic FTD involving 23 research centres across Europe and Canada (www.genfi.org.uk)² involving symptomatic carriers of mutations in *GRN*, *MAPT* or *C9orf72*, and those at risk of carrying a mutation because a first-degree relative was a known symptomatic carrier. Four hundred sixty-nine consecutively recruited individuals from the GENFI study were included: 114 *C9orf72* expansion carriers (74 presymptomatic, 40 symptomatic), 119 *GRN* mutation carriers (88 presymptomatic, 31 symptomatic), 53 *MAPT* mutation carriers (34 presymptomatic, 19 symptomatic) and 183 non-carriers who acted as a control group. Demographic information is shown in [table 1](#): age and sex differed significantly between groups. All people in the study underwent a clinical assessment consisting of a medical history with the participant and informant, and physical examination, with symptomatic status diagnosed by a clinician who was an expert in the FTD field^{20–24} (specific diagnoses are shown in [table 1](#)). All participants underwent a standardised examination including the Mini-Mental State Examination (MMSE) and the Frontotemporal Lobar Degeneration-Clinical Dementia Rating scale (FTLD-CDR).²⁵ Participants also performed three-dimensional

T1-weighted MRI of the brain: 432 scans were available for cross-sectional analysis, of which a subgroup of 243 participants had a follow-up scan (on the same scanner) for analysis (mean (SD) interval 1.12 (0.29) years between baseline and follow-up). Volumetric measures of whole brain and cortical regions were calculated using a previously described method that uses the geodesic information flow (GIF) algorithm, which is based on atlas propagation and label fusion (online supplementary table 1).^{3, 26} An annualised longitudinal rate of atrophy was found by calculating the difference in each specific measure between the baseline and longitudinal scan and expressing it as a percentage of the baseline volume over 1 year (online supplementary table 2).

Measurement of plasma markers

Plasma was collected, processed and stored in aliquots at -80°C according to standardised procedures. Samples were measured using the multiplex Neurology 4-Plex A kit (102153, Quanterix, Lexington, USA) on the SIMOA HD-1 Analyzer following manufacturer's instructions. The lower limit of detection of the assay for GFAP and NfL were 0.221 and 0.104 pg/mL, respectively. Measurements were carried out at the same study site on consecutive days and the operator was blinded to all clinical information, including genetic status. To keep sample processing and plating consistent, plasma samples were thawed at room temperature for 2 hours and subsequently centrifuged at 10 000g for 5 min; 150 μL samples were aliquoted in a 96-well plate (Quanterix) and frozen at -80°C until analysis. Quality control samples had a mean intra-assay and interassay coefficient of variation of $< 10\%$.

Statistical analysis

Fisher's exact test was used to compare sex frequencies between groups. Distributions for demographic and biomarker data

were investigated graphically using histograms and quantile-quantile plots and tested for normality using the Shapiro-Wilk test. As demographic data did not follow a normal distribution, group differences for age at sample collection and FTLD-CDR-Sum Of Boxes were compared using the Kruskal-Wallis test. A linear regression adjusting for age was used to compare MMSE scores between groups. The primary analysis in the study was to investigate whether there were any differences in plasma GFAP concentration from controls in the different genetic mutation groups both symptomatically and presymptotically, as well as between genetic groups. As biomarker values were not normally distributed, group means were compared by performing a linear mixed regression model with 95% bias-corrected bootstrapped CIs with 2000 repetitions in STATA (V.14; StataCorp, College Station, Texas, USA), adjusting for age and sex with family membership included as a random effect. Diagnostic performance of GFAP was assessed by areas under the curve (AUC) obtained by receiver operating characteristic (ROC) analyses, with optimal cut-off levels at the highest Youden's index (sensitivity+specificity-1) using GraphPad Prism (V.6; GraphPad Software, San Diego, California, USA). In order to investigate the relationship of GFAP concentration to demographic, cognitive and imaging measures as well as NfL concentrations, Spearman's correlation coefficient was used.

RESULTS

Plasma GFAP concentration

Plasma GFAP concentration was significantly higher in the symptomatic *GRN* mutation carriers compared with controls (adjusted mean difference 192.3 pg/mL, 95% CI 126.5 to 445.6), but not in either the symptomatic *C9orf72* (9.0, -61.3 to 54.6) or *MAPT* (12.7, -33.3 to 90.4) groups (figure 1, tables 1 and 2). Within the symptomatic groups, concentrations in *GRN* were significantly higher than both *C9orf72* (183.3, 106.1 to 427.2) and *MAPT* (179.6, 99.8 to 348.1) mutation carriers.

A ROC curve analysis measuring the ability of GFAP to distinguish symptomatic *GRN* mutation carriers from controls showed a sensitivity of 90.3% and specificity of 82.0% with a cut-off point of 163.2 pg/mL and an AUC of 0.90. For distinguishing symptomatic *GRN* mutation carriers from *C9orf72* mutation carriers there was a sensitivity of 71.0% and specificity of 70.0% with a cut-off point of 226.2 pg/mL and an AUC of 0.74, while for distinguishing symptomatic *GRN* mutation carriers from *MAPT* mutation carriers there was a sensitivity of 79.0% and specificity of 77.4% with a cut-off point of 209.1 pg/mL and an AUC of 0.80 (online supplementary figure 1).

In the presymptomatic groups, concentrations were not significantly increased in any of the groups compared with controls: *GRN* (14.2, -2.4 to 38.3), *C9orf72* (21.1, -18.8 to 66.5), *MAPT* (-7.0, -61.8 to 7.8) (figure 1, tables 1 and 2). There were also no differences across the presymptomatic groups.

Comparing symptomatic and presymptomatic carriers, a significantly higher concentration was also seen in the symptomatic versus the presymptomatic *GRN* mutation carriers (178.1, 114.3 to 365.2), but not in the other groups (figure 1, tables 1 and 2).

Correlation with age

GFAP concentration was significantly correlated with age at sample collection in controls ($r=0.55$, $p<0.001$), presymptomatic mutation carriers (all groups combined: $r=0.53$, $p<0.001$; *GRN*: $r=0.58$, $p<0.001$; *C9orf72*: $r=0.50$, $p<0.001$; *MAPT*: $r=0.36$, $p=0.036$) and symptomatic mutation carriers for all




Figure 1 (A) Plasma glial fibrillary acidic protein (GFAP) and (B) plasma neurofilament light chain (NfL) concentrations (pg/mL) in control, presymptomatic and symptomatic frontotemporal dementia mutation carriers for each gene: *C9orf72*, *GRN* and *MAPT*. Median designated by blue line; IQRs indicated by orange error bars. *Significant differences—only differences from controls and within the same genetic group are shown on the graph. Note that 29 data points fall outside the upper or lower limit using the IQR method, with factor $k=1.5$ (ie, outside the upper limit $Q3+1.5\times IQR$ or lower limit $Q1-1.5\times IQR$): excluding these outliers does not change the significance of the results.

genetic groups together ($r=0.38$, $p<0.001$) and the *GRN* group alone ($r=0.65$, $p<0.001$) (figure 2). No significant correlation was seen for the symptomatic *C9orf72* ($r=0.27$, $p=0.088$) or *MAPT* mutation carriers ($r=0.00$, $p=0.989$).

Correlation with plasma NfL

Plasma NfL was increased in all three symptomatic groups compared with controls (figure 1, tables 1 and 3): *GRN* mutation carriers (adjusted mean difference 70.5 pg/mL, 95% CI 51.6 to 92.6), *C9orf72* mutation carriers (29.7, 18.7 to 47.5) and *MAPT* mutation carriers (12.6, 3.3 to 26.1). Within the symptomatic groups, concentrations in *GRN* were significantly higher than both *C9orf72* (40.7, 16.5 to 62.2) and *MAPT* (57.9, 36.8

Table 2 Adjusted mean differences in plasma GFAP concentrations between groups with 95% bias-corrected bootstrap CIs

GFAP	<i>C9orf72</i> PS	<i>C9orf72</i> S	<i>GRN</i> PS	<i>GRN</i> S	<i>MAPT</i> PS	<i>MAPT</i> S
Controls	21.1 (−18.8 to 66.5)	9.0 (−61.3 to 54.6)	14.2 (−2.4 to 38.3)	192.3** (126.5 to 445.6)	−7.0 (−61.8 to 7.8)	12.7 (−33.3 to 90.4)
<i>C9orf72</i> PS		12.1 (−64.1 to 85.1)	−6.9 (−51.0 to 43.0)	171.2** (88.5 to 433.7)	−28.1 (−83.3 to 8.0)	8.4 (−87.5 to 74.5)
<i>C9orf72</i> S			−5.2 (−79.4 to 39.4)	183.3** (106.1 to 427.2)	−16.0 (−84.3 to 32.9)	−3.7 (−104.5 to 56.1)
<i>GRN</i> PS				178.1** (114.3 to 365.2)	−21.2 (−78.3 to 1.5)	1.5 (−75.4 to 49.1)
<i>GRN</i> S					−199.3** (−439.2 to −124.9)	−179.6** (−348.1 to −99.8)
<i>MAPT</i> PS						19.6 (−30.8 to 114.4)

Significant differences in bold: **p<0.01.

GFAP, glial fibrillary acidic protein; PS, presymptomatic; S, symptomatic.

to 81.5) mutation carriers, and *C9orf72* mutation carriers were higher than *MAPT* mutation carriers (17.2, 2.9 to 35.7). Concentration was also increased in presymptomatic *C9orf72* mutation carriers compared with controls (9.0, 1.3 to 26.8), but not in the *GRN* or *MAPT* presymptomatic groups (figure 1, tables 1 and 3). Comparing symptomatic and presymptomatic carriers, a significantly higher concentration was also seen in the symptomatic versus the presymptomatic mutation carriers in each of the groups (figure 1, tables 1 and 3): *GRN* mutation carriers (70.5, 52.5 to 92.2), *C9orf72* mutation carriers (20.7, 3.2 to 36.1) and *MAPT* mutation carriers (11.7, 0.8 to 23.4).

Plasma GFAP and NfL concentrations were significantly correlated in controls ($r=0.66$, $p<0.001$), presymptomatic mutation carriers (*GRN*: $r=0.66$, $p<0.001$; *C9orf72*: $r=0.75$, $p<0.001$; *MAPT*: $r=0.41$, $p=0.017$) and symptomatic mutation

carriers (*GRN*: $r=0.38$, $p=0.036$; *C9orf72*: $r=0.57$, $p<0.001$; *MAPT*: $r=0.76$, $p<0.001$).

Correlation with cognitive measures

A significant negative correlation between GFAP concentrations and MMSE was seen in the presymptomatic *GRN* ($r=-0.24$, $p=0.033$) and *C9orf72* ($r=-0.40$, $p<0.001$) but not *MAPT* ($r=0.05$, $p=0.801$) mutation carriers. No significant correlation was seen during the symptomatic period in any of the genetic groups (*GRN*: $r=-0.29$, $p=0.153$; *C9orf72*: $r=-0.24$, $p=0.146$; *MAPT*: $r=-0.48$, $p=0.080$).

No significant correlations were seen between GFAP concentration and FTLD-CDR sum of boxes score in either the presymptomatic or symptomatic period in any group: *GRN*: $r=-0.04$, $p=0.768$ presymptomatic, $r=0.18$, $p=0.409$ symptomatic; *C9orf72*: $r=-0.17$, $p=0.234$ presymptomatic, $r=0.21$, $p=0.321$ symptomatic; *MAPT*: $r=-0.17$, $p=0.446$ presymptomatic, $r=0.14$, $p=0.736$ symptomatic.

Correlation with cross-sectional imaging data

A significant negative correlation was seen between GFAP concentrations and both *GRN* and *C9orf72* presymptomatic carrier brain volumes for frontal cortex ($r=-0.23$, $p=0.039$; $r=-0.35$, $p=0.002$), temporal cortex ($r=-0.35$, $p=0.001$; $r=-0.27$, $p=0.024$), cingulate cortex ($r=-0.24$, $p=0.027$; $r=-0.44$, $p<0.001$) and insular cortex ($r=-0.27$, $p=0.016$; $r=-0.26$, $p=0.029$) as well as whole brain ($r=-0.45$, $p<0.001$) and parietal cortex ($r=-0.33$, $p=0.005$) for the *C9orf72* group (online supplementary table 3). No significant correlations were seen in the presymptomatic *MAPT* mutation carrier group or any of the symptomatic genetic groups.

Correlation with longitudinal imaging data

No significant positive correlation of GFAP concentration with longitudinal rates of atrophy were seen in any of the groups except for in the temporal cortex of symptomatic *GRN* mutation carriers ($r=0.66$, $p=0.010$) (online supplementary table 4). However, within the same symptomatic *GRN* group there was also a trend in relationship between GFAP concentration and atrophy rates in the cingulate cortex ($r=0.55$, $p=0.052$).

DISCUSSION

In this study, we found that plasma GFAP concentration was significantly increased in genetic FTD but only in *GRN* mutation carriers, and not in those with *C9orf72* expansions or mutations




Figure 2 Correlation between plasma glial fibrillary acidic protein (GFAP) concentrations (pg/mL) and age: (A) presymptomatic and (B) symptomatic mutation carriers.

Table 3 Adjusted mean differences in plasma NfL concentrations between groups with 95% bias-corrected bootstrap CI

NfL	<i>C9orf72</i> PS	<i>C9orf72</i> S	<i>GRN</i> PS	<i>GRN</i> S	<i>MAPT</i> PS	<i>MAPT</i> S
Controls	9.0* (1.3 to 26.8)	29.7** (18.7 to 47.5)	0.0 (−3.1 to 3.3)	70.5** (51.6 to 92.6)	0.9 (−2.2 to 6.4)	12.6* (3.3 to 26.1)
<i>C9orf72</i> PS		20.7* (3.2 to 36.1)	−9.0* (−27.5 to −1.4)	61.4** (37.7 to 82.7)	−8.1* (−27.0 to −0.6)	3.6 (−15.6 to 17.0)
<i>C9orf72</i> S			−29.8** (−47.7 to −18.7)	40.7** (16.5 to 62.2)	−28.9** (−46.2 to −16.9)	−17.2* (−35.7 to −2.9)
<i>GRN</i> PS				70.5** (52.5 to 92.2)	−0.9 (−5.9 to 2.9)	12.6* (2.9 to 25.2)
<i>GRN</i> S					−69.6** (−91.7 to −50.6)	−57.9** (−81.5 to −36.8)
<i>MAPT</i> PS						11.7* (0.8 to 23.4)

Significant differences in bold: * $p < 0.05$; ** $p < 0.01$.

NfL, neurofilament light chain; PS, presymptomatic; S, symptomatic.

in the *MAPT* gene. In the presymptomatic period, higher concentrations were correlated with a lower cognitive score (MMSE) and lower brain volumes (in regions characteristically affected in FTD), potentially suggesting GFAP is increased in the late presymptomatic period. In the symptomatic period, higher concentrations were associated with faster rates of atrophy, suggesting GFAP levels are associated with disease intensity, and therefore progression and survival.

GFAP is a major constituent of the astrocytic cytoskeleton and its expression pattern is highly brain-enriched.²⁷ Its levels increase following acute damage to astrocytes such as after a stroke²⁸ or traumatic brain injury,²⁹ but also in relation to more chronic insults, such as in neurodegeneration, when astrocytes become reactive, increasing in size and proliferating, a process called astrogliosis.²⁷ In neurodegeneration, increased GFAP concentrations in biofluid have been reported in Alzheimer's disease³⁰ (in both CSF^{17 19} and serum¹⁹) and amyotrophic lateral sclerosis¹⁸. Previous studies in FTD have found increased CSF concentrations in symptomatic patients within combined clinical^{17 19} and genetic cohorts¹⁸ but have not previously found changes in blood,¹⁹ nor investigated individual genetic groups previously. Our results suggest that there are differential increases within FTD, with concentrations being higher in people with *GRN* mutations than in other groups. *GRN* encodes the progranulin protein, which is a secreted growth factor and known to be involved in many biological processes including inflammation, wound healing and cell proliferation.^{31 32} However, progranulin is also taken up by astrocytes for storage or transportation to the lysosomal compartment,^{33–35} and studies of *GRN*-deficient mice have shown the presence of astrogliosis.^{35–37} In vitro, progranulin seems to have a role of inactivating astrocytes with evidence that progranulin attenuates a pro-inflammatory phenotype of astrocytes.³⁵ This suggests that deficiency of progranulin in *GRN* mutation carriers may lead to activation of pro-inflammatory phenotypes of astrocytes and subsequent astrogliosis, with increased levels of GFAP expression. People with *GRN* mutations have evidence of astrogliosis pathologically, including within areas of white matter damage³⁸ (visible in a proportion of people in vivo as white matter hyperintensities on MR imaging, which have been previously shown to be unique to *GRN* mutations within familial FTD).³⁹ Such damage increases as the neurodegeneration progresses,³⁹ consistent with the pattern of increased plasma GFAP in our study. In contrast, levels were not increased in plasma in individuals with *C9orf72* expansions or *MAPT* mutations. While astrogliosis is seen in animal models and

at postmortem in both *C9orf72*-related⁴⁰ and *MAPT*-related^{41 42} FTD, this may well be a late feature of the disease, or the extent of astrogliosis may be less. Future work will be required to investigate this further.

It is well established that multiple biomarkers of neurodegeneration increase in concentration with age, attributed to the reduction of neural integrity in the ageing brain.⁴³ CSF GFAP concentrations have previously been shown to increase as one gets older,⁴⁴ with multiple studies showing proliferation of astrocytes, increased GFAP immunoreactivity and elevated levels of GFAP mRNA with age.^{45–49} Consistent with this, we also found a significant positive correlation of plasma GFAP concentration with age in the majority of the groups. This highlights the importance of adjusting plasma GFAP concentrations for age in statistical analyses: symptomatic mutation carriers in the *C9orf72* and *MAPT* groups (as well as the *GRN* group) in this study showed increased levels of plasma GFAP compared with controls and their presymptomatic counterparts, but significance was lost once adjusting for age.

NfL, part of the axonal cytoskeleton, is released following cellular damage. A previous study has shown that NfL concentrations are increased in both the CSF and blood of symptomatic genetic FTD in all three mutation groups, *C9orf72*, *GRN* and *MAPT*.³ The results in this study replicate these findings in plasma, although we also found elevated levels in presymptomatic *C9orf72* mutation carriers. In this latter group, NfL concentrations correlated negatively with MMSE ($r = -0.33$, $p = 0.004$: online supplementary table 5) and with brain volumes (whole brain, $r = -0.53$, $p < 0.001$ and cortical regions: frontal, -0.51 , < 0.001 ; temporal, -0.37 , 0.001 ; parietal, -0.51 , < 0.001 ; occipital, -0.33 , 0.005 ; cingulate, -0.49 , < 0.001 ; insula, -0.47 , < 0.001 : online supplementary tables 6 and 7), suggesting that NfL increases particularly towards the end of the presymptomatic period with increasing neurodegeneration. Although *GRN* NfL concentration was not significantly increased presymptomatically, a similar pattern of negative correlation with brain volumes was seen in this group (in whole brain and all cortical regions except the occipital lobe, $r = -0.30$ to -0.48 , $p \leq 0.006$). NfL and GFAP concentrations were significantly correlated in all groups including controls, although the correlation coefficient varied from 0.38 to 0.76. A similar correlation has been shown in CSF previously.⁴⁴ As both increase with age (online supplementary table 8 for NfL correlations with age), the correlation is not unexpected, but other unexplained factors are likely to affect the different patterns within genetic FTD; interestingly,

the lowest correlation ($r=0.38$) was in the symptomatic *GRN* mutation carriers, suggesting that in this group astrogliosis and neurodegeneration are not so closely related.

Correlation of GFAP concentration with cognitive and imaging measures revealed a negative correlation, that is, higher concentration with a lower cognitive score and lower cross-sectional brain volumes in FTD-related regions in presymptomatic *GRN* mutation carriers. This suggests that GFAP levels start to increase as the brain starts to decrease in volume, and as cognition starts to become affected thus in the later stages of the presymptomatic period in proximity to symptom onset. This would be an important biomarker for *GRN*-related FTD, as an increase in concentration from baseline during the presymptomatic period would identify a time around the onset of neurodegeneration, and potentially a time when therapeutic intervention may be optimal. Despite the lack of a significant increase in concentration in *C9orf72* mutation carriers, a similar pattern of negative correlation with cognition and brain imaging was seen in the presymptomatic period—it would be useful in future studies to investigate the subset of *C9orf72* expansion carriers that have increased GFAP concentrations, and how they differ from those with a lower concentration. In particular, it would be helpful to compare carriers with and without concomitant ALS. We also assessed whether GFAP correlated with the rate of brain atrophy measured with longitudinal brain imaging and found a significant positive correlation only in the symptomatic *GRN* carriers (in the temporal lobe), implicating an association of GFAP levels with the intensity of the disease process, that is, how fast the disease is progressing. With longitudinal follow-up of participants, it would therefore be hypothesised that higher GFAP concentration would be associated with shorter survival in *GRN*-related FTD.

While the multicentre nature of the GENFI study allows collection of samples from a large genetic cohort of FTD worldwide, there remains a relatively small number of cases in each group (leading to low statistical power to detect differences), particularly in the symptomatic carriers, and replication in a larger dataset would be helpful. Due to the nature of the disease process, the mean age of the controls overall is lower compared with the symptomatic mutation carriers, but nonetheless the same results are found whether performing an age-adjusted comparison (as presented above in **Plasma GFAP concentration**) or when symptomatic mutation carriers are compared with an age-matched and gender-matched subset of older controls (see online supplementary figure 2). The advantage of studying levels in plasma is that blood is more easily accessible and a relatively cost-efficient way to access bodily fluids in comparison to performing a lumbar puncture; in this study, the use of the ultrasensitive SIMOA assay allowed detection at a level in blood that other assays do not. However, it will be important to study CSF levels in more detail in this group, as concentrations can differ between blood and CSF.¹⁸ Lastly, despite significant differences between the groups, there is a substantial overlap in concentrations between carriers and controls: longitudinal study of GFAP concentration over time, particularly in participants that convert from presymptomatic to symptomatic status, will therefore be important to truly evaluate whether changes do occur towards the end of the presymptomatic period and how levels change with progression of disease.

In summary, plasma GFAP levels appear to be uniquely increased in *GRN* mutation carriers in the current study, and importantly, concentrations may well be abnormal during the late presymptomatic period, suggesting that GFAP might act as marker of proximity to symptom onset.

Author affiliations

- ¹UK Dementia Research Institute, Department of Neurodegenerative Disease, University College London, London, UK
- ²Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
- ³Centre for Medical Image Computing, University College London, London, UK
- ⁴Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology, London, UK
- ⁵Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands
- ⁶Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, País Vasco, Spain
- ⁷Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain
- ⁸Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
- ⁹Clinique Interdisciplinaire de Mémoire du CHU de Québec, Département des Sciences Neurologiques, Université Laval, Québec, Québec, Canada
- ¹⁰Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
- ¹¹Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada
- ¹²Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden
- ¹³Department of Biomedical, Surgical and Dental Sciences, University of Milan, Centro Dino Ferrari, Milan, Italy
- ¹⁴Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
- ¹⁵Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
- ¹⁶Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada
- ¹⁷Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, Tübingen, Germany
- ¹⁸German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany
- ¹⁹Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
- ²⁰Faculty of Medicine, University of Lisbon, Lisbon, Portugal
- ²¹Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologico Carlo Besta, Milan, Italy
- ²²Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- ²³Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada
- ²⁴Department of Clinical Neurology, University of Oxford, Oxford, UK
- ²⁵Faculty of Medical and Human Sciences, Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK
- ²⁶German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- ²⁷Department of Neurology, Ludwig-Maximilians-University, Munich, Germany
- ²⁸Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- ²⁹IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy
- ³⁰Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence, Florence, Italy
- ³¹Department of Neurology, University of Ulm, Ulm, Germany
- ³²Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

Twitter Martha S Foiani @marthafoiani, David Thomas @dave_mri and Simon Ducharme @sducharme66

Acknowledgements The authors would like to thank the members of the kindreds who have been active participants in the GENFI study.

Collaborators Martin N Rossor, Jason D Warren (Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK); Nick C Fox (Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK); Dementia Research Institute, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; Rita Guerreiro, Jose Bras (Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, Michigan, USA); Jennifer Nicholas (Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK); Simon Mead (MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK); Lize Jiskoot, Lieke Meeter, Jessica Panman, Janne Papma (Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands); Rick van Minkelen (Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, Netherlands); Yolanda Pijnenburg (Amsterdam University Medical Centre, Amsterdam VUmc, Amsterdam, Netherlands); Myriam Barandiaran, Begoña Indakoetxea (Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain); Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain; Alazne Gabilondo, Mikel Tainta, Maria de Arriba, Ana Gorostidi, Miren Zulaica (Neuroscience Area, Biodonostia Health

Research Institute, San Sebastian, Gipuzkoa, Spain); Jorge Villanua (OSATEK, University of Donostia, San Sebastian, Gipuzkoa, Spain); Zigor Diaz (CITA Alzheimer, San Sebastian, Gipuzkoa, Spain); Sergi Borrego-Ecija, Jaume Olives, Albert Lladó, Mircea Balasa, Anna Antonell (Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Barcelona, Spain); Nuria Bargallo (Imaging Diagnostic Center, Hospital Clinic, Barcelona, Spain); Enrico Premi, Maura Cosseddu, Stefano Gazzina, Alessandro Padovani (Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy); Roberto Gasparotti (Neuroradiology Unit, University of Brescia, Brescia, Italy); Silvana Archetti (Biotechnology Laboratory, Department of Diagnostics, Spedali Civili Hospital, Brescia, Italy); Sandra Black, Sara Mitchell (Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada); Ekaterina Rogava (Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada); Morris Freedman (Baycrest Health Sciences, Rotman Research Institute, University of Toronto, Toronto, Canada); Ron Keren (The University Health Network, Toronto Rehabilitation Institute, Toronto, Canada); David Tang-Wai (The University Health Network, Krembil Research Institute, Toronto, Canada); Linn Öijersted (Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden); Christin Andersson (Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden); Vesna Jelic (Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden); Hakan Thonberg (Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden); Andrea Arighi, Chiara Fenoglio, Elio Scarpini (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy); University of Milan, Centro Dino Ferrari, Milan, Italy); Giorgio Fumagalli (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy); University of Milan, Centro Dino Ferrari, Milan, Italy); Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy); Thomas Cope, Carolyn Timberlake, Timothy Rittman (Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK); Christen Shoesmith (Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada); Robert Bartha (Department of Medical Biophysics, The University of Western Ontario, London, Ontario, Canada); Centre for Functional and Metabolic Mapping, Robarts Research Institute, The University of Western Ontario, London, Ontario, Canada); Rosa Rademakers (Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA); Carlo Wilke (Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany); Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany); Hans-Otto Karnath (Division of Neuropsychology, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany); Benjamin Bender (Department of Diagnostic and Interventional Neuroradiology, University of Tübingen, Tübingen, Germany); Rose Bruffaerts (Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium); Philip Vandamme (Neurology Service, University Hospitals Leuven, Laboratory for Neurobiology, VIB-KU Leuven Centre for Brain Research, Leuven, Belgium); Mathieu Vandenbulcke (Geriatric Psychiatry Service, University Hospitals Leuven, Belgium); Catarina B Ferreira (Laboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal); Gabriel Miltenberger (45Faculty of Medicine, University of Lisbon, Lisbon, Portugal); Carolina Maruta (Laboratory of Language Research, Centro de Estudos Egas Moniz, Faculty of Medicine, University of Lisbon, Lisbon, Portugal); Ana Verdelho (Department of Neurosciences and Mental Health, Centro Hospitalar Lisboa Norte - Hospital de Santa Maria & Faculty of Medicine, University of Lisbon, Lisbon, Portugal); Sónia Afonso (Instituto Ciências Nucleares Aplicadas a Saude, Universidade de Coimbra, Coimbra, Portugal); Ricardo Taipa (Neuropathology Unit and Department of Neurology, Centro Hospitalar do Porto - Hospital de Santo António, Oporto, Portugal); Paola Caroppo, Giuseppe Di Fede, Giorgio Giaccone, Sara Prioni, Veronica Redaelli, Giacomina Rossi, Pietro Tiraboschi (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy); Diana Duro, Maria Rosario Almeida, Miguel Castelo-Branco (Faculty of Medicine, University of Coimbra, Coimbra, Portugal); Maria João Leitão (Centre of Neurosciences and Cell biology, Universidade de Coimbra, Coimbra, Portugal); Miguel Tabuas-Pereira, Beatriz Santiago (Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal); Serge Gauthier (Alzheimer Disease Research Unit, McGill Centre for Studies in Aging, Department of Neurology & Neurosurgery, McGill University, Montreal, Québec, Canada); Pedro Rosa-Neto (Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill University, Montreal, Québec, Canada); Michele Veldsman (Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK); Toby Flanagan (Faculty of Biology, Medicine and Health, Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK); Catharina Prix, Tobias Hoegen, Elisabeth Wlasich, Sandra Loosli, Sonja Schonecker (Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany); Elisa Semler, Sarah Anderl-Straub (Department of Neurology, University of Ulm, Ulm); Luisa Benussi, Giuliano Binetti, Roberta Ghidoni, Michela Pievani (Istituto di Recovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy); Gemma Lombardi, Benedetta

Nacmias, Camilla Ferrari, Valentina Bessi (Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence, Florence, Italy).

Contributors CH and JR contributed to the study design, acquisition, analysis and interpretation of the data as well as drafting and revising the manuscript. All other authors (MSF, AJH, HZ, KM, RC, MB, MN, DMC, DT, CVG, IOCW, RS, JCVS, FM, RS-V, BB, RrL, MM, MCT, CG, DG, JBR, EF, MS, RV, AdeM, FT, IS, SD, CRB, AG, JL, AD, GF, SS, MO) contributed to the acquisition of data and study coordination as well as helping to critically review and revise the manuscript.

Funding The GENFI study has been supported by the Medical Research Council UK (MR/M023664/1), the Italian Ministry of Health and the Canadian Institutes of Health Research as part of a Centres of Excellence in Neurodegeneration grant, as well as other individual funding to investigators. This work was supported by the NIHR Queen Square Dementia Biomedical Research Unit, the NIHR UCL/H Biomedical Research Centre and the Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility, Alzheimer's Research UK, the Brain Research Trust and the Wolfson Foundation as well as an Alzheimer's Society grant (AS-PG-16-007). The biomarker measurements were funded in part by the UK Dementia Research Institute at UCL and by a Wellcome Trust Multi-User Equipment Grant. KM has received funding from an Alzheimer's Society PhD studentship. IOCW is supported by a MRC Clinical Research Training Fellowship (MR/M018288/1). RS-V is supported by an Alzheimer's Research UK Clinical Research Training Fellowship (ARUK-CRF2017B-2). JCVS was supported by the Dioraphte Foundation grant 09-02-03-00, the Association for Frontotemporal Dementias Research Grant 2009, The Netherlands Organization for Scientific Research (NWO) grant HCMI 056-13-018, ZonMw Memorabel (Deltaplanning Dementie, project number 733 051 042), Alzheimer Nederland and the Bluefield project. CG received funding from JPND-Prefrontals VR Dnr 529-2014-7504, VR 2015-02926 and 2018-02754, the Swedish FTD Initiative-Schörling Foundation, Alzheimer Foundation, Brain Foundation and Stockholm County Council ALF. DG received support from the EU Joint Programme—Neurodegenerative Disease Research (JPND) and the Italian Ministry of Health (PreFrontALS) grant 733051042. RS-V has received funding from Fundació Marató de TV3, Spain (grant no. 20143810). FM received funding from the Tau Consortium and the Center for Networked Biomedical Research on Neurodegenerative Disease (CIBERNED). JBR has received funding from the Wellcome Trust (103838) and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. MO has received funding from BMBF (FTLDC). MM has received funding from a Canadian Institutes of Health Research operating grant and the Weston Brain Institute and Ontario Brain Institute. RV has received funding from the Mady Browaeys Fund for Research into Frontotemporal Dementia. EF has received funding from a CIHR grant #327387. HZ is a Wallenberg Academy Fellow. JR is a MRC Clinician Scientist (MR/M008525/1) and has received funding from the NIHR Rare Diseases Translational Research Collaboration (BRC149/NS/MH), the Bluefield Project and the Association for Frontotemporal Degeneration.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Local ethics committees at each site approved the study and all participants provided written informed consent at enrolment.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Some GENFI data is available on reasonable request through application to the GENFI Data Access Committee.

ORCID iDs

Carolin Heller <http://orcid.org/0000-0002-1934-6162>
 Martha S Foiani <http://orcid.org/0000-0003-4157-2606>
 Katrina Moore <https://orcid.org/0000-0002-4458-8390>
 Rhian Convery <http://orcid.org/0000-0002-9477-1812>
 Martina Bocchetta <http://orcid.org/0000-0003-1814-5024>
 Mollie Neason <https://orcid.org/0000-0001-9419-7171>
 David Thomas <https://orcid.org/0000-0003-1491-1641>
 Caroline V Greaves <https://orcid.org/0000-0002-6446-1960>
 lone OC Woollacott <https://orcid.org/0000-0003-1166-6417>
 Rachelle Shafei <https://orcid.org/0000-0002-4760-8684>
 John C Van Swieten <http://orcid.org/0000-0001-6278-6844>
 Barbara Borroni <http://orcid.org/0000-0001-9340-9814>
 James B Rowe <http://orcid.org/0000-0001-7216-8679>
 Elizabeth Finger <http://orcid.org/0000-0003-4461-7427>
 Markus Otto <http://orcid.org/0000-0002-6647-5944>
 Jonathan D Rohrer <https://orcid.org/0000-0002-6155-8417>

REFERENCES

- 1 Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. *J Neurochem* 2016;138 Suppl 1:6–31.

- 2 Rohrer JD, Nicholas JM, Cash DM, *et al.* Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the genetic frontotemporal dementia initiative (GENFI) study: a cross-sectional analysis. *Lancet Neurol* 2015;14:253–62.
- 3 Meeter LH, Doppler EG, Jiskoot LC, *et al.* Neurofilament light chain: a biomarker for genetic frontotemporal dementia. *Ann Clin Transl Neurol* 2016;3:623–36.
- 4 Galimberti D, Fumagalli GG, Fenoglio C, *et al.* Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. *Neurobiol Aging* 2018;62:245.e9–e12.
- 5 Meeter LHH, Gendron TF, Sias AC, *et al.* Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. *Ann Clin Transl Neurol* 2018;5:583–97.
- 6 Meeter LHH, Patzke H, Loewen G, *et al.* Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers. *Dement Geriatr Cogn Dis Extra* 2016;6:330–40.
- 7 Gendron TF, Chew J, Stankowski JN, *et al.* Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. *Sci Transl Med* 2017. [Epub ahead of print: 29 Mar 2017].
- 8 Lehmer C, Oeckl P, Weishaupt JH, *et al.* Poly- GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS / FTD. *EMBO Mol Med* 2017;9:859–68.
- 9 Scherling CS, Hall T, Berisha F, *et al.* Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. *Ann Neurol* 2014;75:116–26.
- 10 Skillbäck T, Mattsson N, Blennow K, *et al.* Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. *Amyotroph Lateral Scler Frontotemporal Degener* 2017;18:397–403.
- 11 Lewczuk P, Ermann N, Andreasson U, *et al.* Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. *Alzheimers Res Ther* 2018;10.
- 12 Rohrer JD, Woollacott IOC, Dick KM, *et al.* Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. *Neurology* 2016;87:1329–36.
- 13 Wilke C, Preische O, Deuschle C, *et al.* Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. *J Neurol Neurosurg Psychiatry* 2016;87:1270–2.
- 14 Skillbäck T, Farahmand B, Bartlett JW, *et al.* CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. *Neurology* 2014;83:1945–53.
- 15 Colangelo AM, Alberghina L, Papa M. Astroglia as a therapeutic target for neurodegenerative diseases. *Neurosci Lett* 2014;565:59–64.
- 16 Umoh ME, Dammer EB, Dai J, *et al.* A proteomic network approach across the ALS - FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. *EMBO Mol Med* 2018;10:48–62.
- 17 Ishiki A, Kamada M, Kawamura Y, *et al.* Glial fibrillary acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. *J Neurochem* 2016;136:258–61.
- 18 Oeckl P, Weydt P, Steinacker P, *et al.* Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. *J Neurol Neurosurg Psychiatry* 2019;90:4–10.
- 19 Oeckl P, Halbgebauer S, Anderl-Straub S, *et al.* Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. *JAD* 2019;67:481–8.
- 20 Rascovsky K, Hodges JR, Knopman D, *et al.* Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 2011;134:2456–77.
- 21 Gorno-Tempini ML, Hillis AE, Weintraub S, *et al.* Classification of primary progressive aphasia and its variants. *Neurology* 2011;76:1006–14.
- 22 Brooks BR, Miller RG, Swash M, *et al.* El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2000;1:293–9.
- 23 Armstrong MJ, Litvan I, Lang AE, *et al.* Criteria for the diagnosis of corticobasal degeneration. *Neurology* 2013;80:496–503.
- 24 Höglinger GU, Respondek G, Stamelou M, *et al.* Clinical diagnosis of progressive supranuclear palsy: the movement disorder Society criteria. *Mov Disord* 2017;32:853–64.
- 25 Knopman DS, Kramer JH, Boeve BF, *et al.* Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. *Brain* 2008;131:2957–68.
- 26 Cardoso MJ, Modat M, Wolz R, *et al.* Geodesic information flows: Spatially-Variant graphs and their application to segmentation and fusion. *IEEE Trans Med Imaging* 2015;34:1976–88.
- 27 Liddel SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. *Immunity* 2017;46:957–67.
- 28 Dvorak F, Haberer I, Sitzer M, *et al.* Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. *Cerebrovasc Dis* 2009;27:37–41.
- 29 Papa L, Silvestri S, Brophy GM, *et al.* Gfap outperforms S100β in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions. *J Neurotrauma* 2014;31:1815–22.
- 30 Olsson B, Lautner R, Andreasson U, *et al.* CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. *Lancet Neurol* 2016;15:673–84.
- 31 Cenik B, Sephton CF, Kutluk Cenik B, *et al.* Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. *J Biol Chem* 2012;287:32298–306.
- 32 Chitramuthu BP, Bennett HPJ, Bateman A. Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. *Brain* 2017;140:3081–104.
- 33 Almeida S, Zhou L, Gao F-B. Progranulin, a glycoprotein deficient in frontotemporal dementia, is a novel substrate of several protein disulfide isomerase family proteins. *PLoS One* 2011;6:e26454.
- 34 Menzel L, Kleber L, Friedrich C, *et al.* Progranulin protects against exaggerated axonal injury and astroglia following traumatic brain injury. *Glia* 2017;65:278–92.
- 35 Petkau TL, Hill A, Leavitt BR. Core neuropathological abnormalities in progranulin-deficient mice are penetrant on multiple genetic backgrounds. *Neuroscience* 2016;315:175–95.
- 36 Ghoshal N, Dearborn JT, Wozniak DF, *et al.* Core features of frontotemporal dementia recapitulated in progranulin knockout mice. *Neurobiol Dis* 2012;45:395–408.
- 37 Yin F, Banerjee R, Thomas B, *et al.* Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. *J Exp Med* 2010;207:117–28.
- 38 Woollacott IOC, Bocchetta M, Sudre CH, *et al.* Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia. *Neurocase* 2018;24:166–74.
- 39 Sudre CH, Bocchetta M, Cash D, *et al.* White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. *Neuroimage Clin* 2017;15:171–80.
- 40 Chew J, Gendron TF, Prudencio M, *et al.* Neurodegeneration. C9orf72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. *Science* 2015;348:1151–4.
- 41 Hallmann A-L, Araúzo-Bravo MJ, Mavrommatis L, *et al.* Astrocyte pathology in a human neural stem cell model of frontotemporal dementia caused by mutant tau protein. *Sci Rep* 2017;7.
- 42 Domoto-Reilly K, Davis MY, Keene CD, *et al.* Unusually long duration and delayed penetrance in a family with FTD and mutation in MAPT (V337M). *Am J Med Genet B Neuropsychiatr Genet* 2017;174:70–4.
- 43 Raz N, Rodrigue KM. Differential aging of the brain: patterns, cognitive correlates and modifiers. *Neurosci Biobehav Rev* 2006;30:730–48.
- 44 Vågberg M, Norgren N, Dring A, *et al.* Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction. *PLoS One* 2015;10:e0135886.
- 45 Hayakawa N, Kato H, Araki T. Age-related changes of astrocytes, oligodendrocytes and microglia in the mouse hippocampal CA1 sector. *Mech Ageing Dev* 2007;128:311–6.
- 46 Cotrina ML, Nedergaard M. Astrocytes in the aging brain. *J Neurosci Res* 2002;67:1–10.
- 47 Kohama SG, Goss JR, Finch CE, *et al.* Increases of glial fibrillary acidic protein in the aging female mouse brain. *Neurobiol Aging* 1995;16:59–67.
- 48 Goss JR, Finch CE, Morgan DG. Age-Related changes in glial fibrillary acidic protein mRNA in the mouse brain. *Neurobiol Aging* 1991;12:165–70.
- 49 Lynch AM, Murphy KJ, Deighan BF, *et al.* The impact of glial activation in the aging brain. *Aging Dis* 2010;1:262–78.